Fig. 1: Low SUCNR1 predicts acute myeloid leukemia progression.

A–B Kaplan–Meier analysis of acute myeloid leukemia (AML) patient survival data analyzed as a function of SUCNR1 expression in AML blasts (GSE14468, n = 426). SUCNR1 expression levels were discretized as high or low based on the median SUCNR1 expression level for the whole cohort. p value indicates likelihood ratio test. A Analysis of overall survival. B Analysis of progression-free survival. C SUCNR1 expression in patients categorized as M0-M3 (n = 224) and M4-M5 (n = 171) in GSE14468. D SUCNR1 expression in total bone marrow (TBM) of healthy donors or AML patients, data were extracted from Bloodspot repository using TARGET AML database, normal cells are from GSE42519 and AML cells are from GSE13159. E Treatment with succinic acid or vehicle of NSG mice for 10 days, starting 20 weeks after the transplant with CD34⁺ progenitors isolated from the BM of one M1 AML patient. TBM fraction of human CD33⁺ (hCD33⁺) blasts analyzed by fluorescence-activated cell sorting (n = 6 per group). Statistical analyses were performed with log-rank Mantel-Cox test (A, B), two-tailed Student’s t test (C, D) or two-tailed Mann–Whitney U test (E). Significant p-values are reported. Data are biologically independent human samples or animals, and means ± SEM for bar plots or medians for violin plots. Box plots in (C) show median as center line; upper and lower quartiles as box limits; 1.5x interquartile range as whiskers. Source data are provided as a Source Data file.